✦ LIBER ✦

EXPRESSION AND FUNCTIONAL ACTIVITY OF BREAST CANCER RESISTANCE PROTEIN (BCRP, ABCG2) TRANSPORTER IN THE HUMAN CHORIOCARCINOMA CELL LINE BEWO

✍ Scribed by Martina Ceckova; Antonin Libra; Petr Pavek; Petr Nachtigal; Marianne Brabec; Renate Fuchs; Frantisek Staud

Book ID: 108937737
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 228 KB
Volume: 33
Category: Article
ISSN: 0305-1870
DOI: 10.1111/j.1440-1681.2006.04324.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

[Handbook of Experimental Pharmacology]

[Handbook of Experimental Pharmacology] Drug Transporters Volume 201 || In Vitro and In Vivo Evidence for the Importance of Breast Cancer Resistance Protein Transporters (BCRP/MXR/ABCP/ABCG2)

✍ Fromm, Martin F.; Kim, Richard B. 📂 Article 📅 2010 🏛 Springer Berlin Heidelberg ⚖ 387 KB

Expression and Functional Activity of th

Expression and Functional Activity of the ABC-transporter Proteins P-glycoprotein and Multidrug-resistance Protein 1 in Human Brain Tumor Cells and Astrocytes

✍ Sabine Spiegl-Kreinecker; Johanna Buchroithner; Leonilla Elbling; Elisabeth Stei 📂 Article 📅 2002 🏛 Springer US 🌐 English ⚖ 646 KB

Inhibition of extracellular signal-regul

Inhibition of extracellular signal-regulated kinase1/2 activity of the breast cancer cell line MDA-MB-231 leads to major alterations in the pattern of protein expression

✍ Maria Seddighzadeh; Stig Linder; Maria C. Shoshan; Gert Auer; Ayodele A. Alaiya 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 368 KB

CCAAT/enhancer binding protein δ (C/EBPδ

CCAAT/enhancer binding protein δ (C/EBPδ) regulation and expression in human mammary epithelial cells: I. “Loss of function” alterations in the C/EBPδ growth inhibitory pathway in breast cancer cell lines

✍ G.S. Sivko; J.W. DeWille 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 428 KB 👁 1 views

## Abstract “Loss of function” alterations in growth inhibitory signal transduction pathways are common in cancer cells. In this study, we show that growth arrest (GA) treatments—serum and growth factor withdrawal and growth inhibitory IL‐6 family cytokines (Interleukin‐6 and Oncostatin M (OSM))—in